Vincerx Pharma
Palo Alto
About Vincerx Pharma
Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx’s executive team has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation antibody-drug conjugate platform.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $16.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2024)
- Ticker: nasdaq:VINC
- Website: vincerx.com
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Oncology
Social Profiles
Canonical: https://fsome.com/organization/vincerx-pharma-111726 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.